Fortrea Holdings Inc. (NASDAQ: FTRE) saw its stock price surge 7.97% in pre-market trading on Monday, following the release of its better-than-expected first-quarter 2025 financial results. The clinical research organization delivered a significant earnings beat and surpassed revenue expectations, demonstrating resilience in a challenging market environment.
The company reported quarterly earnings of $0.02 per share, surpassing the analyst consensus estimate of $(0.07) by 128.57%. This represents a remarkable 140% improvement from the losses of $(0.05) per share reported in the same period last year. Fortrea's quarterly sales reached $651.30 million, exceeding the analyst consensus estimate of $608.34 million by 7.06%. However, it's worth noting that this figure still represents a slight 1.63% decrease compared to sales of $662.10 million in the same quarter of the previous year.
Despite facing challenges, including a non-cash goodwill impairment charge that resulted in a GAAP net loss of $(562.9) million, Fortrea's adjusted EBITDA of $30.3 million and a book-to-bill ratio of 1.02x for the quarter (1.14x for the trailing 12 months) signal underlying strength in the business. The company's ability to outperform expectations in a difficult operating environment has clearly resonated with investors, driving the significant pre-market stock price increase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.